Reimbursement, Not Off-Label Use, May Be Hindering Carotid Stent Trials
This article was originally published in The Gray Sheet
Executive Summary
Enrollment of randomized trials of carotid stents in low-risk patients has been slow because many doctors have an economic incentive to prevent their patients from being randomized, according to Kenneth Rosenfield, M.D., Massachusetts General Hospital
You may also be interested in...
Stakeholders Urge Caution In Medicare Coverage Of Carotid Stenting
Opponents of expanded Medicare coverage for carotid artery stenting procedures fear that reimbursement would lead to overutilization and disrupt enrollment in clinical trials that could help collect more detailed outcomes evidence
Stakeholders Urge Caution In Medicare Coverage Of Carotid Stenting
Opponents of expanded Medicare coverage for carotid artery stenting procedures fear that reimbursement would lead to overutilization and disrupt enrollment in clinical trials that could help collect more detailed outcomes evidence
New CDRH Decision Methods Will Be Put To The Test, Starting With Stents
Defining a "new science" for post-market surveillance is a top priority for the FDA device center's post-market group, according to the program's new leader